1. T2DM, CV Risk, and SGLT2 Inhibition in the Spotlight

2. SGLT2 Inhibition

4. EMPA-REG OUTCOME: Study Design

5. EMPA-REG OUTCOME: Key Inclusion and Exclusion Criteria

6. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on the Primary Composite Outcome

7. EMPA-REG OUTCOME : Effect of Empagliflozin vs Placebo on Individual MACE Endpoints

8. EMPA-REG OUTCOME: Effect of Empagliflozin vs Placebo on CV Death

9. EMPA-REG OUTCOME: HF Hospitalization or CV Death

10. EMPA-REG OUTCOME: HF Hospitalization or Death from HF

11. EMPA-REG OUTCOME: Investigator-Reported HF

12. EMPA-REG OUTCOME: HF Hospitalization in Patients With vs Without HF at Baseline

13. EMPA-REG OUTCOME: HF Hospitalization or CV Death in Patients With vs Without HF at Baseline

14. EMPA-REG OUTCOME: CV Medication Use

15. ADA/EASD Position Statement: Antihyperglycemic Therapy in T2DM

16. EMPA-REG OUTCOME: Baseline CV Complications

17. Ongoing SGLT2 Inhibitor CV Outcomes Trials

18. Abbreviations

19. Abbreviations (cont)